Protalix BioTherapeutics, Inc. financial data

Symbol
PLX on NYSE
Location
Hackensack, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 263% % 78%
Quick Ratio 87% % 99%
Debt-to-equity 61% % -63%
Return On Equity 11% %
Return On Assets 7% %
Operating Margin 10% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 80,421,181 shares 9.2%
Common Stock, Shares, Outstanding 75,850,275 shares 4%
Entity Public Float $82,000,000 USD -41%
Common Stock, Value, Issued $76,000 USD 4.1%
Weighted Average Number of Shares Outstanding, Basic 79,281,685 shares 7.8%
Weighted Average Number of Shares Outstanding, Diluted 80,814,564 shares -0.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $61,840,000 USD 35%
Cost of Revenue $26,260,000 USD -10%
Research and Development Expense $18,058,000 USD 51%
Operating Income (Loss) $6,367,000 USD -47%
Nonoperating Income (Expense) $117,000 USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $6,484,000 USD -42%
Income Tax Expense (Benefit) $1,090,000 USD 5956%
Net Income (Loss) Attributable to Parent $5,394,000 USD -27%
Earnings Per Share, Basic 0 USD/shares -25%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $13,647,000 USD -50%
Accounts Receivable, after Allowance for Credit Loss, Current $14,425,000 USD 557%
Inventory, Net $21,255,000 USD 24%
Other Assets, Current $1,452,000 USD 38%
Assets, Current $66,502,000 USD 39%
Deferred Income Tax Assets, Net $2,679,000 USD -6.2%
Property, Plant and Equipment, Net $4,724,000 USD 1.6%
Operating Lease, Right-of-Use Asset $7,810,000 USD 38%
Assets $82,264,000 USD 34%
Accounts Payable, Current $19,577,000 USD 4.5%
Employee-related Liabilities, Current $745,000 USD -40%
Accrued Liabilities, Current $8,126,000 USD -2.6%
Contract with Customer, Liability, Current $12,695,000 USD
Liabilities, Current $21,945,000 USD -9.4%
Operating Lease, Liability, Noncurrent $6,780,000 USD 62%
Liabilities $29,356,000 USD 0.79%
Retained Earnings (Accumulated Deficit) $378,393,000 USD 0.83%
Stockholders' Equity Attributable to Parent $52,908,000 USD 63%
Liabilities and Equity $82,264,000 USD 34%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,058,000 USD -221%
Net Cash Provided by (Used in) Financing Activities $5,076,000 USD
Net Cash Provided by (Used in) Investing Activities $312,000 USD 49%
Common Stock, Shares Authorized 185,000,000 shares 0%
Common Stock, Shares, Issued 75,850,275 shares 4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $302,000 USD -108%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13,647,000 USD -50%
Interest Paid, Excluding Capitalized Interest, Operating Activities $766,000 USD -29%
Deferred Tax Assets, Valuation Allowance $50,665,000 USD -1.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability $8,177,000 USD
Depreciation $346,000 USD 7.5%
Payments to Acquire Property, Plant, and Equipment $306,000 USD -49%
Lessee, Operating Lease, Liability, to be Paid $26,925,000 USD
Property, Plant and Equipment, Gross $40,330,000 USD 1.7%
Operating Lease, Liability, Current $1,397,000 USD -7.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,141,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $1,397,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 7.8%
Deferred Income Tax Expense (Benefit) $177,000 USD -87%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $18,748,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,074,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $50,014,000 USD -2.8%
Current Income Tax Expense (Benefit) $175,000 USD -207%
Preferred Stock, Shares Authorized 100,000,000 shares
Unrecognized Tax Benefits $805,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,040,000 USD
Operating Lease, Payments $457,000 USD 11%
Deferred Tax Assets, Net of Valuation Allowance $2,856,000 USD -7.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares